Roche Holding, CH1499059983

Roche Holding stock: FDA clears Wilserdly and Gazyva

Published on 11/21/2026 at 12:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Roche secured two US FDA approvals and a diagnostics authorization during the week. Roche Holding stock now has several regulatory milestones to track.

Roche adds three regulatory catalysts

  • Wilserdly won US approval for a defined advanced breast cancer population.
  • Gazyva/Gazyvaro became the first FDA-approved treatment for primary membranous nephropathy.
  • The cobas pro i 601 authorization expands Roche's automated mass spectrometry offering.
Roche Holding, CH1499059983, Illustration mit AI erstellt.

Roche secured two important US regulatory decisions on Monday, November 16, 2026. The US Food and Drug Administration approved Wilserdly in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, according to Roche.

The same day, the FDA approved Gazyva/Gazyvaro for adults with primary membranous nephropathy who face a risk of disease progression. Roche said the treatment became the first FDA-approved therapy for the condition. In the phase III MAJESTY study, complete remission of proteinuria at two years reached 36.1% with Gazyva/Gazyvaro, compared with 5.7% with tacrolimus, as reported in a separate Roche investor update.

Oncology and immunology expand

Wilserdly gives Roche a new oral option for patients whose disease has progressed after endocrine treatment and prior CDK4/6 inhibitor therapy. Roche said the phase III evERA study showed a 62% reduction in the risk of disease progression or death versus standard endocrine therapy combined with everolimus. The FDA is also reviewing Wilserdly for adjuvant treatment, with a decision date set for November 30, 2026.

Gazyva/Gazyvaro adds another approved use for Roche's immune-mediated disease portfolio. The FDA is evaluating a further application in systemic lupus erythematosus, with a decision expected by December 2026.

Diagnostics broadens its platform

Roche Diagnostics also reported on November 16 that the FDA granted De Novo authorization for the cobas pro i 601 platform with the Ionify Gabapentin assay. The authorization expands the company's automated mass spectrometry menu into therapeutic drug monitoring. Roche said an authorized change-control plan could support the future expansion of up to 22 Ionify assays, subject to applicable requirements, according to Roche Diagnostics.

Roche Holding stock traded at 426.68 euros on Lang & Schwarz at 12:21 CET on Saturday, November 21, 2026.

Roche Holding stock at a glance

  • Company: Roche Holding AG
  • ISIN: CH1499059983
  • Trading symbols: RO and ROP on SIX; RHHBY on OTCQX
  • Current quote: 426.68 euros on Lang & Schwarz, Saturday, November 21, 2026, 12:21 CET
  • Key milestones: Wilserdly and Gazyva/Gazyvaro FDA approvals; cobas pro i 601 FDA authorization

The broader Swiss market can be followed in the current market reports.

More news and analyses on Roche Holding stock

Disclaimer...
en | CH1499059983 | ROCHE HOLDING | boerse | 70542470 | bgmi